{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:59:52Z","timestamp":1790049592807,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"phase 2 consortium through NCI","award":["N01 CM17104"],"award-info":[{"award-number":["N01 CM17104"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,8,15]]},"DOI":"10.1007\/s10637-019-00797-1","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T05:14:08Z","timestamp":1559798048000},"page":"755-762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9640-4055","authenticated-orcid":false,"given":"Hao","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Menefee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith C.","family":"Bible","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Reidy-Lagunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine A.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Erlichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"issue":"1","key":"797_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1245\/s10434-014-3944-7","volume":"22","author":"BM Dy","year":"2015","unstructured":"Dy BM, Strajina V, Cayo AK et al (2015) Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol 22(1):146\u2013151. https:\/\/doi.org\/10.1245\/s10434-014-3944-7","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"797_CR2","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.surg.2013.06.033","volume":"154","author":"BM Dy","year":"2013","unstructured":"Dy BM, Wise KB, Richards ML et al (2013) Operative intervention for recurrent adrenocortical cancer. Surgery 154(6):1292\u20131299; discussion 1299. https:\/\/doi.org\/10.1016\/j.surg.2013.06.033","journal-title":"Surgery"},{"issue":"23","key":"797_CR3","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMoa063360","volume":"356","author":"M Terzolo","year":"2007","unstructured":"Terzolo M, Angeli A, Fassnacht M et al (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356(23):2372\u20132380. https:\/\/doi.org\/10.1056\/NEJMoa063360","journal-title":"N Engl J Med"},{"issue":"10","key":"797_CR4","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3","volume":"83","author":"A Berruti","year":"1998","unstructured":"Berruti A, Terzolo M, Pia A et al (1998) Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of adrenal Cancer. Cancer 83(10):2194\u20132200","journal-title":"Cancer"},{"issue":"23","key":"797_CR5","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366(23):2189\u20132197. https:\/\/doi.org\/10.1056\/NEJMoa1200966","journal-title":"N Engl J Med"},{"issue":"2","key":"797_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1677\/ERC-09-0281","volume":"17","author":"P Sperone","year":"2010","unstructured":"Sperone P, Ferrero A, Daffara F et al (2010) Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second\u2212\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 17(2):445\u2013453. https:\/\/doi.org\/10.1677\/ERC-09-0281","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"797_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht M, Berruti A, Baudin E et al (2015) Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol 16(4):426\u2013435. https:\/\/doi.org\/10.1016\/S1470-2045(15)70081-1","journal-title":"Lancet Oncol"},{"issue":"10","key":"797_CR8","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1210\/jc.2012-1419","volume":"97","author":"M Kroiss","year":"2012","unstructured":"Kroiss M, Quinkler M, Johanssen S et al (2012) Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 97(10):3495\u20133503. https:\/\/doi.org\/10.1210\/jc.2012-1419","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"797_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.euf.2015.06.005","volume":"1","author":"L Ferrari","year":"2016","unstructured":"Ferrari L, Claps M, Grisanti S et al (2016) Systemic therapy in locally advanced or metastatic adrenal cancers: a critical appraisal and clinical trial update. Eur Urol Focus 1(3):298\u2013300. https:\/\/doi.org\/10.1016\/j.euf.2015.06.005","journal-title":"Eur Urol Focus"},{"issue":"2","key":"797_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"M Fassnacht","year":"2009","unstructured":"Fassnacht M, Johanssen S, Quinkler M et al (2009) Limited prognostic value of the 2004 International Union against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115(2):243\u2013250. https:\/\/doi.org\/10.1002\/cncr.24030","journal-title":"Cancer"},{"issue":"4","key":"797_CR11","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers O, Else T et al (2018) European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol 179(4):G1\u2013G46. https:\/\/doi.org\/10.1530\/EJE-18-0608","journal-title":"Eur J Endocrinol"},{"key":"797_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1749-6632.2002.tb04338.x","volume":"968","author":"LS Kirschner","year":"2002","unstructured":"Kirschner LS (2002) Signaling pathways in adrenocortical cancer. Ann N Y Acad Sci 968:222\u2013239","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"797_CR13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1067\/msy.2002.128616","volume":"132","author":"H Kanauchi","year":"2002","unstructured":"Kanauchi H, Wada N, Clark OH, Duh QY (2002) Apoptosis regulating genes, bcl-2 and bax, and human telomerase reverse transcriptase messenger RNA expression in adrenal tumors: possible diagnostic and prognostic importance. Surgery 132(6):1021\u20131026; discussion 1026-7. https:\/\/doi.org\/10.1067\/msy.2002.128616","journal-title":"Surgery"},{"issue":"1","key":"797_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1023\/A:1006267902186","volume":"43","author":"P Bushunow","year":"1999","unstructured":"Bushunow P, Reidenberg MM, Wasenko J et al (1999) Gossypol treatment of recurrent adult malignant gliomas. J Neuro-Oncol 43(1):79\u201386","journal-title":"J Neuro-Oncol"},{"issue":"4","key":"797_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1210\/jcem.76.4.8473376","volume":"76","author":"MR Flack","year":"1993","unstructured":"Flack MR, Pyle RG, Mullen NM et al (1993) Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 76(4):1019\u20131024. https:\/\/doi.org\/10.1210\/jcem.76.4.8473376","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"797_CR16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/BF00685601","volume":"30","author":"RC Stein","year":"1992","unstructured":"Stein RC, Joseph AE, Matlin SA et al (1992) A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol 30(6):480\u2013482","journal-title":"Cancer Chemother Pharmacol"},{"key":"797_CR17","unstructured":"Investigator\u2019s Brochure (2006) AT-101 [R-(\u2212)-gossypol acetic acid]. Ascenta Therapeutics, Inc. Accessed 31 Mar 2006"},{"issue":"2","key":"797_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0304-3835(98)00302-4","volume":"135","author":"MD Shelley","year":"1999","unstructured":"Shelley MD, Hartley L, Fish RG et al (1999) Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines. Cancer Lett 135(2):171\u2013180","journal-title":"Cancer Lett"},{"issue":"9","key":"797_CR19","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1158\/1078-0432.CCR-08-2985","volume":"15","author":"G Liu","year":"2009","unstructured":"Liu G, Kelly WK, Wilding G et al (2009) An open-label, multicenter, phase I\/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 15(9):3172\u20133176. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2985","journal-title":"Clin Cancer Res"},{"issue":"10","key":"797_CR20","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1097\/JTO.0b013e3181e8f4dc","volume":"5","author":"RS Heist","year":"2010","unstructured":"Heist RS, Fain J, Chinnasami B et al (2010) Phase I\/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 5(10):1637\u20131643. https:\/\/doi.org\/10.1097\/JTO.0b013e3181e8f4dc","journal-title":"J Thorac Oncol"},{"issue":"2","key":"797_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"1","key":"797_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38(1):143\u2013151","journal-title":"Biometrics"},{"issue":"3","key":"797_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176\u2013181. https:\/\/doi.org\/10.1016\/S1053-4296(03)00031-6","journal-title":"Semin Radiat Oncol"},{"issue":"14","key":"797_CR24","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/jnci\/djr218","volume":"103","author":"MR Sharma","year":"2011","unstructured":"Sharma MR, Stadler WM, Ratain MJ (2011) Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 103(14):1093\u20131100. https:\/\/doi.org\/10.1093\/jnci\/djr218","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"797_CR25","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1097\/JTO.0b013e31822e2941","volume":"6","author":"MQ Baggstrom","year":"2011","unstructured":"Baggstrom MQ, Qi Y, Koczywas M et al (2011) A phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol 6(10):1757\u20131760. https:\/\/doi.org\/10.1097\/JTO.0b013e31822e2941","journal-title":"J Thorac Oncol"},{"issue":"4","key":"797_CR26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/JTO.0b013e31820a0ea6","volume":"6","author":"N Ready","year":"2011","unstructured":"Ready N, Karaseva NA, Orlov SV et al (2011) Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol 6(4):781\u2013785. https:\/\/doi.org\/10.1097\/JTO.0b013e31820a0ea6","journal-title":"J Thorac Oncol"},{"issue":"7","key":"797_CR27","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/annonc\/mdr555","volume":"23","author":"G Sonpavde","year":"2012","unstructured":"Sonpavde G, Matveev V, Burke JM et al (2012) Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 23(7):1803\u20131808. https:\/\/doi.org\/10.1093\/annonc\/mdr555","journal-title":"Ann Oncol"},{"issue":"1","key":"797_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clgc.2015.09.010","volume":"14","author":"MN Stein","year":"2016","unstructured":"Stein MN, Hussain M, Stadler WM et al (2016) A phase II study of AT-101 to overcome Bcl-2--mediated resistance to androgen deprivation therapy in patients with newly diagnosed castration-sensitive metastatic prostate Cancer. Clin Genitourin Cancer 14(1):22\u201327. https:\/\/doi.org\/10.1016\/j.clgc.2015.09.010","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"797_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10637-016-0364-5","volume":"34","author":"PL Swiecicki","year":"2016","unstructured":"Swiecicki PL, Bellile E, Sacco AG et al (2016) A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Investig New Drugs 34(4):481\u2013489. https:\/\/doi.org\/10.1007\/s10637-016-0364-5","journal-title":"Investig New Drugs"},{"issue":"5","key":"797_CR30","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","volume":"75","author":"M Kroiss","year":"2011","unstructured":"Kroiss M, Quinkler M, Lutz WK et al (2011) Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol 75(5):585\u2013591. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04214.x","journal-title":"Clin Endocrinol"},{"issue":"9","key":"797_CR31","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1210\/jc.2008-0065","volume":"93","author":"MQ Almeida","year":"2008","unstructured":"Almeida MQ, Fragoso MCBV, Lotfi CFP et al (2008) Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metab 93(9):3524\u20133531. https:\/\/doi.org\/10.1210\/jc.2008-0065","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"797_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.2953","volume":"46","author":"G Assi\u00e9","year":"2014","unstructured":"Assi\u00e9 G, Letouz\u00e9 E, Fassnacht M et al (2014) Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 46(6):607\u2013612. https:\/\/doi.org\/10.1038\/ng.2953","journal-title":"Nat Genet"},{"issue":"3","key":"797_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/MED.0000000000000332","volume":"24","author":"J Varghese","year":"2017","unstructured":"Varghese J, Habra MA (2017) Update on adrenocortical carcinoma management and future directions. Curr Opin Endocrinol Diabetes Obes 24(3):208\u2013214. https:\/\/doi.org\/10.1097\/MED.0000000000000332","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"797_CR34","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"Zheng S, Cherniack AD, Dewal N et al (2016) Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 29(5):723\u2013736. https:\/\/doi.org\/10.1016\/j.ccell.2016.04.002","journal-title":"Cancer Cell"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00797-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00797-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00797-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:34:56Z","timestamp":1678559696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00797-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,6]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8,15]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00797-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,6]]},"assertion":[{"value":"7 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Hao Xie declares that he has no conflict of interest. Jun Yin declares that she has no conflict of interest. Manisha H. Shah declares that she has no conflict of interest related to AT-101 except research funding from Bristol-Myers Squibb for a clinical trial in last 2\u00a0years. Michael E. Menefee declares that he has no conflict of interest. Keith C. Bible declares that he has no conflict of interest. Diane Reidy-Lagunes declares that she receives research funds from Novartis, Ipsen, and Merck, and is on the advisory board for Novartis, Ipsen, AAA, and Lexicon. Madeleine A. Kane declares that she has no conflict of interest. David I. Quinn declares that he has no conflict of interest. David R. Gandara declares that he has no conflict of interest. Charles Erlichman declares that he has no conflict of interest. Alex A. Adjei declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}